{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:43:06Z","timestamp":1786538586959,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Korea Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2022R1C1C1005415"],"award-info":[{"award-number":["NRF-2022R1C1C1005415"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111260","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:03:01Z","timestamp":1762185781000},"page":"111260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk-based selection of treatment strategies in hepatocellular carcinoma with macrovascular invasion"],"prefix":"10.1016","volume":"214","author":[{"given":"Nalee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-7263","authenticated-orcid":false,"given":"Jeong Il","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong Geun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ji","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonseok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geum-Youn","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Han","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Hyeok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsuk","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5728-4839","authenticated-orcid":false,"given":"Sung Wook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Ki","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongho","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111260_b0005","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.radonc.2025.111260_b0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.radonc.2025.111260_b0015","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.radonc.2015.11.019","article-title":"Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: an external validation study","volume":"118","author":"Yu","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111260_b0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2025.111260_b0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and Safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111260_b0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000529635","article-title":"Impact of intrahepatic external beam radiotherapy in advanced hepatocellular carcinoma patients treated with tyrosine kinase inhibitors","volume":"12","author":"Goh","year":"2023","journal-title":"Liver Can"},{"key":"10.1016\/j.radonc.2025.111260_b0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111260_b0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2019.08.009","article-title":"Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C","volume":"141","author":"Kim","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111260_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109841","article-title":"External validation of subclassification system and progression pattern analysis in hepatocelluar carcinoma with macroscopic vascular invasion","volume":"187","author":"Yu","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111260_b0050","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2025.111260_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210730","article-title":"Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients","volume":"14","author":"Sinn","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2025.111260_b0060","doi-asserted-by":"crossref","first-page":"350","DOI":"10.17998\/jlc.2023.08.10","article-title":"Nomogram for predicting overall survival in patients with large (>5 cm) hepatocellular carcinoma based on real-world practice","volume":"23","author":"Kim","year":"2023","journal-title":"J Liver Can"},{"key":"10.1016\/j.radonc.2025.111260_b0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111260_b0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000479984","article-title":"Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function","volume":"6","author":"Hiraoka","year":"2017","journal-title":"Liver Can"},{"key":"10.1016\/j.radonc.2025.111260_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000521374","article-title":"Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Can"},{"key":"10.1016\/j.radonc.2025.111260_b0080","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1159\/000439101","article-title":"General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan","volume":"33","author":"Kudo","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.radonc.2025.111260_b0085","doi-asserted-by":"crossref","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. Doi: 10.3350\/cmh.2022.0294.","DOI":"10.3350\/cmh.2022.0294"},{"key":"10.1016\/j.radonc.2025.111260_b0090","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ijrobp.2011.03.019","article-title":"Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes","volume":"82","author":"Yoon","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111260_b0095","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3346\/jkms.2012.27.7.736","article-title":"Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma","volume":"27","author":"Yu","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.radonc.2025.111260_b0100","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20120221","article-title":"Evaluation of anatomical landmark position differences between respiration-gated MRI and four-dimensional CT for radiation therapy in patients with hepatocellular carcinoma","volume":"86","author":"Yu","year":"2013","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.111260_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051116","article-title":"Chemoembolization plus radiotherapy versus chemoembolization plus sorafenib for the treatment of hepatocellular carcinoma invading the portal vein: a propensity score matching analysis","volume":"12","author":"Chu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111260_b0110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijrobp.2024.09.024","article-title":"Antiangiogenic treatment facilitates the abscopal effect of radiation therapy combined with anti-PD-1 in hepatocellular carcinoma","volume":"121","author":"Sheng","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111260_b0115","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.ijrobp.2023.07.001","article-title":"Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma","volume":"118","author":"Ning","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111260_b0120","doi-asserted-by":"crossref","first-page":"9350","DOI":"10.1038\/s41467-024-53704-5","article-title":"Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:20:54Z","timestamp":1786537254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"alternative-id":["S0167814025052648"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111260","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-based selection of treatment strategies in hepatocellular carcinoma with macrovascular invasion","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111260"}}